Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome

Basit Öğe Kaydı
dc.contributor.authorErturk, Biray
dc.contributor.authorKaraca, Emin
dc.contributor.authorAykut, Ayca
dc.contributor.authorDurmaz, Burak
dc.contributor.authorGuler, Ahmet
dc.contributor.authorBuke, Baris
dc.contributor.authorYeniel, Ahmet Ozgur
dc.contributor.authorErgenoglu, Ahmet Mete
dc.contributor.authorÖzkınay, Ferda
dc.contributor.authorOzeren, Mehmet
dc.contributor.authorKazandi, Mert
dc.contributor.authorAkercan, Fuat
dc.contributor.authorSagol, Sermet
dc.contributor.authorGunduz, Cumhur
dc.contributor.authorCogulu, Ozgur
dc.date.accessioned2019-10-27T22:58:16Z
dc.date.available2019-10-27T22:58:16Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies.en_US
dc.description.sponsorshipEge University Faculty of MedicineEge Universityen_US
dc.description.sponsorshipThis paper is funded by Ege University Faculty of Medicine.en_US
dc.identifier.doi10.1155/2016/5312674en_US
dc.identifier.issn2314-6133
dc.identifier.issn2314-6141
dc.identifier.pmid27110565en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1155/2016/5312674
dc.identifier.urihttps://hdl.handle.net/11454/51498
dc.identifier.wosWOS:000373461800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHindawi Ltden_US
dc.relation.ispartofBiomed Research Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titlePrenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu